Terms: = Liver cancer AND MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7 AND Clinical Outcome
11 results:
1. Development and evaluation of a risk score model based on a WNT score gene-associated signature for predicting the clinical outcome and the tumour microenvironment of hepatocellular carcinoma.
Li P; Ma X; Huang D; Gu X
Int J Immunopathol Pharmacol; 2023; 37():3946320231218179. PubMed ID: 38054921
[No Abstract] [Full Text] [Related]
2. Identification of survival-related predictors in hepatocellular carcinoma through integrated genomic, transcriptomic, and proteomic analyses.
Dong F; Yang Q; Wu Z; Hu X; Shi D; Feng M; Li J; Zhu L; Jiang S; Bao Z
Biomed Pharmacother; 2019 Jun; 114():108856. PubMed ID: 30981109
[TBL] [Abstract] [Full Text] [Related]
3. LKB1 pro-oncogenic activity triggers cell survival in circulating tumor cells.
Trapp EK; Majunke L; Zill B; Sommer H; Andergassen U; Koch J; Harbeck N; Mahner S; Friedl TWP; Janni W; Rack B; Alunni-Fabbroni M
Mol Oncol; 2017 Nov; 11(11):1508-1526. PubMed ID: 28700115
[TBL] [Abstract] [Full Text] [Related]
4. B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer.
Meshcheryakova A; Tamandl D; Bajna E; Stift J; Mittlboeck M; Svoboda M; Heiden D; Stremitzer S; Jensen-Jarolim E; Grünberger T; Bergmann M; Mechtcheriakova D
PLoS One; 2014; 9(6):e99008. PubMed ID: 24905750
[TBL] [Abstract] [Full Text] [Related]
5. Mycotoxins are conventional and novel risk biomarkers for hepatocellular carcinoma.
Matsuda Y; Wakai T; Kubota M; Osawa M; Sanpei A; Fujimaki S
World J Gastroenterol; 2013 May; 19(17):2587-90. PubMed ID: 23674865
[TBL] [Abstract] [Full Text] [Related]
6. clinical impact of hepatitis B and C virus envelope glycoproteins.
Jeulin H; Velay A; Murray J; Schvoerer E
World J Gastroenterol; 2013 Feb; 19(5):654-64. PubMed ID: 23429668
[TBL] [Abstract] [Full Text] [Related]
7. Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer.
Manzoni M; Rovati B; Ronzoni M; Loupakis F; Mariucci S; Ricci V; Gattoni E; Salvatore L; Tinelli C; Villa E; Danova M
Oncology; 2010; 79(3-4):187-96. PubMed ID: 21358206
[TBL] [Abstract] [Full Text] [Related]
8. Biomarker discovery in urogenital cancer.
Said J
Biomarkers; 2005 Nov; 10 Suppl 1():S83-6. PubMed ID: 16298916
[TBL] [Abstract] [Full Text] [Related]
9. Molecular therapy and prevention of hepatocellular carcinoma.
Blum HE
Hepatobiliary Pancreat Dis Int; 2003 Feb; 2(1):11-22. PubMed ID: 14599923
[TBL] [Abstract] [Full Text] [Related]
10. Pyothorax-associated lymphoma: a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B- and T-cell phenotype.
Petitjean B; Jardin F; Joly B; Martin-Garcia N; Tilly H; Picquenot JM; Brière J; Danel C; Mehaut S; Abd-Al-Samad I; Copie-Bergman C; Delfau-Larue MH; Gaulard P
Am J Surg Pathol; 2002 Jun; 26(6):724-32. PubMed ID: 12023576
[TBL] [Abstract] [Full Text] [Related]
11. Absence of p53 gene mutations in hepatocarcinomas from a Mediterranean area of Spain. A study of 129 archival tumour samples.
Boix-Ferrero J; Pellín A; Blesa R; Adrados M; Llombart-Bosch A
Virchows Arch; 1999 Jun; 434(6):497-501. PubMed ID: 10394883
[TBL] [Abstract] [Full Text] [Related]
